136834-20-3

Basic information

• Product Name: N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine
• Synonyms: N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine;Bz-2'-F-dA;Adenosine, N-benzoyl-2'-deoxy-2'-fluoro-;N-Benzoyl-2'-deoxy-2'-fluoroadenosine;N6-Benzoyl-2'-deoxy-2'-fluoroadenosine
• CAS NO: 136834-20-3
• Molecular Formula: C₁₇H₁₆FN₅O₄
• Molecular Weight: 373.3384432
• Mol File: 136834-20-3.mol

Chemical Properties

• Appearance: /
• Density: 1.67±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 7.87±0.43(Predicted)
• CAS DataBase Reference: N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine(CAS DataBase Reference)
• NIST Chemistry Reference: N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine(136834-20-3)
• EPA Substance Registry System: N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine(136834-20-3)

Safety Data

• Hazardous Substances Data: 136834-20-3(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry Research:
N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine is utilized as a research tool in medicinal chemistry to explore the effects of specific structural modifications on nucleoside analogs. Its unique structure allows scientists to investigate how these changes influence the compound's interactions with biological systems and its potential therapeutic applications.
Used in Drug Discovery:
In the field of drug discovery, N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine serves as a valuable compound for identifying and developing new therapeutic agents. Its modified structure may confer novel biological activities, making it a candidate for the treatment of various diseases and conditions. N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine's potential applications could span across different therapeutic areas, depending on the outcomes of ongoing research and development efforts.

Upstream product

• 5536-17-4 arabinosyl adenine 
• 58-61-7 adenosine 
• 20187-82-0 2'-fluorodeoxyadenosine 
• 98-88-4 benzoyl chloride 
• 136834-19-0 N⁶-benzoyl-9-<2-O-(trifluoromethylsulfonyl)-3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl>adenine 
• 146954-64-5 N⁶-benzoyl-2'-deoxy-2'-fluoro-3',5'-di-O-tetrahydropyran-2-yladenosine 
• 136834-18-9 N⁶-benzoyl-9-(3,5-di-O-tetrahydropyran-2-yl-β-D-arabinofuranosyl)adenine 
• 79896-97-2 N6-benzoyl-9-β-D-arabinofuranosyladenine 

Downstream Products

• 136834-21-4 N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)3-fluoro-4-hydroxytetrahydrofuran-2-yl)9H-purin-6yl)benzamide triethylammonium salt 
• 136834-22-5 N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-3-fluoro-tetrahydrofuran-2-yl]purin-6-yl]benzamide 
• 1244763-23-2 C₄₄H₄₈FN₅O₆Si 

Relevant articles and documents

CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF

Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist.

Cyclic dinucleotide analogues, pharmaceutical composition of analogues and applications of analogues and pharmaceutical composition

The invention discloses cyclic dinucleotide analogues, a pharmaceutical composition of the analogues and applications of the analogues and the pharmaceutical composition. The cyclic dinucleotide analogs (I), an isomer, prodrug, stable isotope derivative or pharmaceutically acceptable salt of the analogs have a structure shown in the specification. The cyclic dinucleotide analogs provided by the invention can be used as regulators of stimulator of interferon genes (STIG) and related signaling pathways, and can effectively treat and/or alleviate multiple types of diseases, including but not limited to malignant tumors, inflammation, autoimmune diseases and infectious diseases; and in addition, the STING regulators can also be used as vaccine adjuvants.

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B

Synthesis and anti-HCV activity of 3′,4′-oxetane nucleosides

Hepatitis C virus afflicts approximately 180 million people worldwide and currently there are no direct acting antiviral agents available to treat this disease. Our first generation nucleoside HCV inhibitor, RG7128 has already established proof-of-concept

INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE

Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1).

Antisense modulation of CD40 ligand expression

Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.

Modulation of CEACAM1 expression

Compounds, compositions and methods are provided for modulating the expression of CEACAM1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding CEACAM1. Methods of using these compounds for modulation of CEACAM1 expression and for diagnosis and treatment of disease associated with expression of CEACAM1 are provided.

ANTISENSE MODULATION OF EDG1 EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of EDG1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG1. Methods of using these compounds for modulation of EDG1 expression and for treatment of diseases associated with expression of EDG1 are provided.

Antisense modulation of EDG5 expression

Antisense compounds, compositions and methods are provided for modulating the expression of EDG5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG5. Methods of using these compounds for modulation of EDG5 expression and for treatment of diseases associated with expression of EDG5 are provided.